Recently, it has been reported that a combination of the chemotherapeutic lomustine with TMZ was beneficial solely for GBM patients with methylated MGMT promoter, further highlighting the prognostic importance of MGMT promoter methylation status determination [29,30,31]. This evidence concerns the gene MGMT and glioblastoma.